Phase I/II Study of TSU-68 for Advanced Hepatocellular Carcinoma
Status:
Completed
Trial end date:
2012-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and efficacy of Orantinib, an oral
tyrosine kinase inhibitor of vascular endothelial growth factor receptor-2, platelet-derived
growth factor receptor, and fibroblast growth factor receptor, in patients with advanced
hepatocellular carcinoma (HCC).